Mettler-Toledo (NYSE:MTD) develops precision instruments for labs and industry within the S&P 500 Index ecosystem.
Somerset has expanded monthly sleep testing capacity by 290% following the adoption of Wesper's direct-to-patient, dropship home sleep testing model, according to a newly released whitepaper detailing ...
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...
Management prioritizes 5%–10% weight loss and acetazolamide titration guided by Frisén grading, OCT, and visual fields; refractory or vision-threatening disease may need ONSF or CSF shunting.
Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...
Evidence is provided suggesting that aggregate neural activity at an early stage of visual processing (V1) can directly contribute to perceptual decisions in humans.
“Start low, go slow.” Geriatric pharmacology texts and recent systematic reviews (e.g., on dosing of oncology drugs) warn ...
Chronic hepatitis D virus (HDV) coinfection in people with chronic hepatitis B is associated with rapid progression to liver cirrhosis and high mortality. In 2020, the estimated global HDV burden ...
Ryan Wagner makes sure bartenders meet exacting standards for foam and temperature as stout sales boom.
Researchers conduct the first meta-analysis comparing hypnotics in OSA patients, finding most are safe but flagging temazepam ...
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results